Home/ Stocks/ BBIO

BridgeBio Pharma, Inc. Common Stock

BBIO XNAS

$84.48 +1.68 (+2.03%) ▲ 15-min delayed

Open

$83.72

High

$85.03

Low

$82.24

Volume

2.15M

Market Cap

$16.22B

About BridgeBio Pharma, Inc. Common Stock

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 839 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$194.51M	$-166,555,000	$-0.84
FY 2025	$502.08M	$-732,938,000	$-3.78
Q2 2025	$110.56M	$-183,758,000	$-0.95
Q1 2025	$116.63M	$-169,608,000	$-0.88

Related Market News

No specific coverage for BBIO yet. Check out our latest market news or earnings calendar.

Get BBIO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BridgeBio Pharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.